New immunotherapy offers hope for recurrent cervical cancer
News
Lynparza approved in Scotland for BRCA-mutated breast cancer patients
Treatment expands options for HER2-negative metastatic breast cancer
Capgemini unveils AI breakthrough to boost bioeconomy
New methodology may boost innovation in protein engineering
Hemgenix shows efficacy among haemophilia B patients
CSL Behring’s study reveals significant long-term benefits
Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
Partnership aims to leverage cutting-edge technology in clinical trials
FDA grants Orphan Drug Designation to Ariceum cancer therapy
Designation follows promising preclinical data and FDA clearance
Novartis secures MHRA authorisation for ribociclib
Breast cancer therapy offers hope for patients at risk of recurrence
Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies
Partnership aims to create recombinant nanobodies to treat immune disorders
Algiax announces results from phase 2a trial for neuropathic pain treatment
Study shows AP-325 offers lasting pain relief without central side effects
Aplagon secures EUR 7 million for APAC phase 2a trials
Funding led by new investors FSG and EIC Fund
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Positive opinion issued for marketing authorisation extension
Cartesian Therapeutics announces FDA agreement for new trial
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25
FDA approves new Alzheimer’s treatment regimen
Patients and care partners may find once every four weeks maintenance dosing easier
Vedanta Biosciences reveals Phase 2 VE303 results
Study highlights VE303’s potential in reducing recurrent CDI
Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX
Comparison shows improved survival rates for pancreatic cancer treatment
